Roni Mamluk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roni Mamluk has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adam Wayne Beck
Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, AL
1 shared publication - Andrew F Miller
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX 75390-8593, USA
1 shared publication - Henry Wong
Adnexus, a Bristol-Myers Squibb Company, Waltham, MA 02453, USA
1 shared publication - Juliet G Carbon
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX 75390-8593, USA
1 shared publication - Laura A Sullivan
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX 75390-8593, USA
1 shared publication - Rolf A. Brekken
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication
Latest Publications
- Open Access
- 27 November 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 352
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of angiogenesis are attractive targets for therapy. Vascular endothelial growth factor (VEGF) is a well-characterized mediator of tumor angiogenesis that functions primarily by binding and activating VEGF receptor 2 (VEGFR2). In this study, we evaluate the use of CT-322, a novel biologic (Adnectin). This small protein is based on a human fibronectin domain and has beneficial properties in that it is fully human, stable, and is produced in bacteria. CT-322 binds to and inhibits activation of VEGFR2.
- 27 November 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 352
Open AccessThe Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of angiogenesis are attractive targets for therapy. Vascular endothelial growth factor (VEGF) is a well-characterized mediator of tumor angiogenesis that functions primarily by binding and activating VEGF receptor 2 (VEGFR2). In this study, we evaluate the use of CT-322, a novel biologic (Adnectin). This small protein is based on a human fibronectin domain and has beneficial properties in that it is fully human, stable, and is produced in bacteria. CT-322 binds to and inhibits activation of VEGFR2.